+1 201 316 9200
+81 (0)3 6264 0600
Europe & Rest of World
+41 61 316 81 11
Lonza’s Epibase® In Silico platform is a patented T cell epitope screening tool for the identification of potential epitopes in biotherapeutic protein and antibody targets. The tool is driven by sequence information, structural bioinformatics, and experimental data. The Epibase® In Silico tool uses structural characteristics of the HLA receptor along with experimentally determined binding affinities to predict potential peptide/HLA binding, a condition necessary for T cell activation.
The Epibase® In Silico tool supports lead candidate selection, ranking, optimization, and design for the development of biotherapeutic proteins and antibodies with reduced immunogenicity risk.
Help Increase Chance of Clinical Success
Save Time and Money in Development